Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
15-week randomized double-blind study of alendronate + vitamin D3 in women with postmenopausal osteoporosis
2010-024150-10Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jul 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alendronate and vitamin d in postmenopausal osteoporosis and Vitamin D deficiency (VDD) (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Proportion of patients with 25-hydroxy vitamin D insufficiency after 15 weeks. Started Jul 2011; status: completed.
02
Drugs
alendronatevitamin d
03
Conditions
postmenopausal osteoporosisVitamin D deficiency (VDD)
Beyond the preview
Go deeper on 2010-024150-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024150-10.